[HTML][HTML] Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
P Guyot, AE Ades, MJNM Ouwens… - BMC medical research …, 2012 - Springer
Background The results of Randomized Controlled Trials (RCTs) on time-to-event outcomes
that are usually reported are median time to events and Cox Hazard Ratio. These do not …
that are usually reported are median time to events and Cox Hazard Ratio. These do not …
Extrapolation of survival curves from cancer trials using external information
P Guyot, AE Ades, M Beasley, B Lueza… - Medical Decision …, 2017 - journals.sagepub.com
Background: Estimates of life expectancy are a key input to cost-effectiveness analysis (CEA)
models for cancer treatments. Due to the limited follow-up in Randomized Controlled Trials …
models for cancer treatments. Due to the limited follow-up in Randomized Controlled Trials …
[HTML][HTML] Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps
Background Among patients with chronic rhinosinusitis with nasal polyps (CRSwNP),
randomized clinical trials (RCTs) of biologics, such as anti-interleukin-4/interleukin-13 (dupilumab) …
randomized clinical trials (RCTs) of biologics, such as anti-interleukin-4/interleukin-13 (dupilumab) …
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
…, L Oddershede, M Yoon, X Wang, P Guyot… - Acta …, 2020 - Taylor & Francis
Background: The analysis of the BRAF mutational status has been established as a standard
procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF …
procedure during diagnosis of advanced malignant melanoma due to the fact that BRAF …
[HTML][HTML] Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with …
A van Walsem, S Pandhi, RM Nixon, P Guyot… - Arthritis research & …, 2015 - Springer
Introduction There is argument over the benefits and risks of drugs for treating chronic
musculoskeletal pain. This study compared the efficacy, safety, and tolerability of diclofenac, …
musculoskeletal pain. This study compared the efficacy, safety, and tolerability of diclofenac, …
[HTML][HTML] Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta …
P Guyot, P Taylor, R Christensen, L Pericleous… - Arthritis research & …, 2011 - Springer
Introduction The goal of this study was to compare the efficacy in terms of Health Assessment
Questionnaire change from baseline (HAQ CFB), 50% improvement in American College …
Questionnaire change from baseline (HAQ CFB), 50% improvement in American College …
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonist s in people with type 2 …
…, C Whittington, S Kanters, P Guyot… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are the recommended first
injectable therapy in type 2 diabetes. However, long‐term persistence is suboptimal and partly …
injectable therapy in type 2 diabetes. However, long‐term persistence is suboptimal and partly …
[HTML][HTML] Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness
P Guyot, NJ Welton, MJNM Ouwens, AE Ades - Value in Health, 2011 - Elsevier
Objectives Many regulatory agencies require that manufacturers establish both efficacy and
cost-effectiveness. The statistical analysis of the randomized, controlled trial (RCT) …
cost-effectiveness. The statistical analysis of the randomized, controlled trial (RCT) …
Insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: a …
P Home, L Blonde, S Kalra, L Ji, P Guyot… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To assess the efficacy and safety of iGlarLixi, a fixed‐ratio combination of insulin glargine
100 U/mL and lixisenatide, relative to premix insulin and other insulin options through …
100 U/mL and lixisenatide, relative to premix insulin and other insulin options through …
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic …
PD Home, VR Aroda, L Blonde, P Guyot… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aims To estimate the relative treatment effect between the fixed‐ratio combinations iGlarLixi
and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with …
and IDegLira (glucagon‐like peptide 1 receptor agonist with basal insulin) in people with …